Cargando…
Physicochemical properties determining drug detection in skin
Chemicals, including some systemically administered xenobiotics and their biotransformations, can be detected noninvasively using skin swabs and untargeted metabolomics analysis. We sought to understand the principal drivers that determine whether a drug taken orally or systemically is likely to be...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932847/ https://www.ncbi.nlm.nih.gov/pubmed/34793633 http://dx.doi.org/10.1111/cts.13198 |
_version_ | 1784671522769600512 |
---|---|
author | Bittremieux, Wout Advani, Rohit S. Jarmusch, Alan K. Aguirre, Shaden Lu, Aileen Dorrestein, Pieter C. Tsunoda, Shirley M. |
author_facet | Bittremieux, Wout Advani, Rohit S. Jarmusch, Alan K. Aguirre, Shaden Lu, Aileen Dorrestein, Pieter C. Tsunoda, Shirley M. |
author_sort | Bittremieux, Wout |
collection | PubMed |
description | Chemicals, including some systemically administered xenobiotics and their biotransformations, can be detected noninvasively using skin swabs and untargeted metabolomics analysis. We sought to understand the principal drivers that determine whether a drug taken orally or systemically is likely to be observed on the epidermis by using a random forest classifier to predict which drugs would be detected on the skin. A variety of molecular descriptors describing calculated properties of drugs, such as measures of volume, electronegativity, bond energy, and electrotopology, were used to train the classifier. The mean area under the receiver operating characteristic curve was 0.71 for predicting drug detection on the epidermis, and the SHapley Additive exPlanations (SHAP) model interpretation technique was used to determine the most relevant molecular descriptors. Based on the analysis of 2561 US Food and Drug Administration (FDA)‐approved drugs, we predict that therapeutic drug classes, such as nervous system drugs, are more likely to be detected on the skin. Detecting drugs and other chemicals noninvasively on the skin using untargeted metabolomics could be a useful clinical advancement in therapeutic drug monitoring, adherence, and health status. |
format | Online Article Text |
id | pubmed-8932847 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89328472022-03-24 Physicochemical properties determining drug detection in skin Bittremieux, Wout Advani, Rohit S. Jarmusch, Alan K. Aguirre, Shaden Lu, Aileen Dorrestein, Pieter C. Tsunoda, Shirley M. Clin Transl Sci Research Chemicals, including some systemically administered xenobiotics and their biotransformations, can be detected noninvasively using skin swabs and untargeted metabolomics analysis. We sought to understand the principal drivers that determine whether a drug taken orally or systemically is likely to be observed on the epidermis by using a random forest classifier to predict which drugs would be detected on the skin. A variety of molecular descriptors describing calculated properties of drugs, such as measures of volume, electronegativity, bond energy, and electrotopology, were used to train the classifier. The mean area under the receiver operating characteristic curve was 0.71 for predicting drug detection on the epidermis, and the SHapley Additive exPlanations (SHAP) model interpretation technique was used to determine the most relevant molecular descriptors. Based on the analysis of 2561 US Food and Drug Administration (FDA)‐approved drugs, we predict that therapeutic drug classes, such as nervous system drugs, are more likely to be detected on the skin. Detecting drugs and other chemicals noninvasively on the skin using untargeted metabolomics could be a useful clinical advancement in therapeutic drug monitoring, adherence, and health status. John Wiley and Sons Inc. 2021-11-28 2022-03 /pmc/articles/PMC8932847/ /pubmed/34793633 http://dx.doi.org/10.1111/cts.13198 Text en © 2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Bittremieux, Wout Advani, Rohit S. Jarmusch, Alan K. Aguirre, Shaden Lu, Aileen Dorrestein, Pieter C. Tsunoda, Shirley M. Physicochemical properties determining drug detection in skin |
title | Physicochemical properties determining drug detection in skin |
title_full | Physicochemical properties determining drug detection in skin |
title_fullStr | Physicochemical properties determining drug detection in skin |
title_full_unstemmed | Physicochemical properties determining drug detection in skin |
title_short | Physicochemical properties determining drug detection in skin |
title_sort | physicochemical properties determining drug detection in skin |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932847/ https://www.ncbi.nlm.nih.gov/pubmed/34793633 http://dx.doi.org/10.1111/cts.13198 |
work_keys_str_mv | AT bittremieuxwout physicochemicalpropertiesdeterminingdrugdetectioninskin AT advanirohits physicochemicalpropertiesdeterminingdrugdetectioninskin AT jarmuschalank physicochemicalpropertiesdeterminingdrugdetectioninskin AT aguirreshaden physicochemicalpropertiesdeterminingdrugdetectioninskin AT luaileen physicochemicalpropertiesdeterminingdrugdetectioninskin AT dorresteinpieterc physicochemicalpropertiesdeterminingdrugdetectioninskin AT tsunodashirleym physicochemicalpropertiesdeterminingdrugdetectioninskin |